These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 2300246)
1. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease. Scigliano G; Musicco M; Soliveri P; Piccolo I; Girotti F; Giovannini P; Caraceni T Neurology; 1990 Feb; 40(2):265-9. PubMed ID: 2300246 [TBL] [Abstract][Full Text] [Related]
2. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Uitti RJ; Ahlskog JE; Maraganore DM; Muenter MD; Atkinson EJ; Cha RH; O'Brien PC Neurology; 1993 Oct; 43(10):1918-26. PubMed ID: 8413948 [TBL] [Abstract][Full Text] [Related]
3. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926 [TBL] [Abstract][Full Text] [Related]
4. Clinical course of patients with idiopathic Parkinson's disease. Roos RA; Jongen JC; van der Velde EA Mov Disord; 1996 May; 11(3):236-42. PubMed ID: 8723138 [TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease patients first treated at age 75 years or older: a comparative study. Peretz C; Chillag-Talmor O; Linn S; Gurevich T; El-Ad B; Silverman B; Friedman N; Giladi N Parkinsonism Relat Disord; 2014 Jan; 20(1):69-74. PubMed ID: 24183677 [TBL] [Abstract][Full Text] [Related]
6. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. Lees AJ BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803 [TBL] [Abstract][Full Text] [Related]
7. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Caraceni T; Scigliano G; Musicco M Neurology; 1991 Mar; 41(3):380-4. PubMed ID: 2006005 [TBL] [Abstract][Full Text] [Related]
8. [Progress in the basic and clinical aspects of Parkinson's disease]. Mizuno Y Rinsho Shinkeigaku; 2004 Nov; 44(11):741-50. PubMed ID: 15651281 [TBL] [Abstract][Full Text] [Related]
9. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Goetz CG; Stebbins GT; Blasucci LM Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412 [TBL] [Abstract][Full Text] [Related]
10. Should levodopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 parkinsonian patients treated with levodopa over 14 years. Indo T; Takahashi A Jpn J Med; 1989; 28(1):30-3. PubMed ID: 2724644 [TBL] [Abstract][Full Text] [Related]
11. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687 [TBL] [Abstract][Full Text] [Related]
12. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Oertel WH; Wolters E; Sampaio C; Gimenez-Roldan S; Bergamasco B; Dujardin M; Grosset DG; Arnold G; Leenders KL; Hundemer HP; Lledó A; Wood A; Frewer P; Schwarz J Mov Disord; 2006 Mar; 21(3):343-53. PubMed ID: 16211594 [TBL] [Abstract][Full Text] [Related]
13. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167 [TBL] [Abstract][Full Text] [Related]
14. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Olanow CW; Myllylä VV; Sotaniemi KA; Larsen JP; Pålhagen S; Przuntek H; Heinonen EH; Kilkku O; Lammintausta R; Mäki-Ikola O; Rinne UK Neurology; 1998 Sep; 51(3):825-30. PubMed ID: 9748034 [TBL] [Abstract][Full Text] [Related]
15. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409 [TBL] [Abstract][Full Text] [Related]
17. Factors that influence the occurrence of response variations in Parkinson's disease. de Jong GJ; Meerwaldt JD; Schmitz PI Ann Neurol; 1987 Jul; 22(1):4-7. PubMed ID: 3631919 [TBL] [Abstract][Full Text] [Related]
18. The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. Hely MA; Morris JG; Traficante R; Reid WG; O'Sullivan DJ; Williamson PM J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):300-7. PubMed ID: 10449550 [TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease in Taiwan: an analysis of 215 patients. Chia LG; Liu LH Neuroepidemiology; 1992; 11(3):113-20. PubMed ID: 1407246 [TBL] [Abstract][Full Text] [Related]